Carfilzomib (Kyprolis®) in combination with lenalidomide and dexamethasone (CAR+LEN+DEX)

Assessment Status NCPE Assessment process complete
Drug Carfilzomib  (in combination with lenalidomide and dexamethasone) 
Brand Kyprolis®
Indication For the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Assessment Process
Rapid review commissioned 07/12/2015
Rapid review completed 06/01/2016
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 24/03/2016
NCPE assessment outcome Reimbursement Not Recommended

Technical Summary

The HSE has approved reimbursement following confidential price negotiations September 2018